Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

NIH 3OTHER 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Prostatic Neoplasms 90Breast Neoplasms 87Melanoma 86Multiple Myeloma 69Carcinoma, Non-Small-Cell Lung 63Leukemia, Myeloid, Acute 62Lymphoma 59Brain Neoplasms 57Glioblastoma 55Ovarian Neoplasms 51Neoplasms 51Carcinoma, Renal Cell 49Lymphoma, Non-Hodgkin 47Fallopian Tube Neoplasms 47Leukemia, Lymphocytic, Chronic, B-Cell 45Sarcoma 44Gliosarcoma 43Neoplasm Metastasis 39Lung Neoplasms 36Carcinoma, Hepatocellular 35Precursor Cell Lymphoblastic Leukemia-Lymphoma 34Pancreatic Neoplasms 33Glioma 33Lymphoma, Large B-Cell, Diffuse 32Uterine Cervical Neoplasms 31Hematologic Neoplasms 31Colonic Neoplasms 31Small Cell Lung Carcinoma 29Myelodysplastic Syndromes 28Rhabdomyosarcoma 27

Interventions

Vincristine 2Rituximab 2Prednisone 2Etoposide 2Doxorubicin 2Cyclophosphamide 2varlilumab 1prednylidene 1deltacortene 1Vorinostat 1Nivolumab 1Immunoglobulin G 1Disulfides 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Has results × Plasmablastic Lymphoma × Clear all
NCT03038672 2026-05-12

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2 Active not recruiting
54 enrolled 12 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphomatoid Granulomatosis, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

NCT01193842 2023-11-21

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas

National Cancer Institute (NCI)

Phase 1/2 Completed
107 enrolled 24 charts
Lymphoid

Plasmablastic Lymphoma, Lymphoma, Follicular, HIV Infections, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

NCT01092182 2023-04-27

Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
194 enrolled 19 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, HIV Seropositivity, HIV Infections, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡